SGTX
Income statement / Annual
Last year (2022), Sigilon Therapeutics, Inc.'s total revenue was $12.94 M,
an increase of 34.85% from the previous year.
In 2022, Sigilon Therapeutics, Inc.'s net income was -$43.46 M.
See Sigilon Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$12.94 M |
$9.60 M |
$13.37 M |
$14.16 M |
$4.64 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$12.94 M
|
$9.60 M
|
$13.37 M
|
$14.16 M
|
$4.64 M
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$37.63 M
|
$65.07 M
|
$53.49 M
|
$48.11 M
|
$21.04 M
|
| General & Administrative Expenses |
$18.98 M
|
$20.17 M
|
$12.53 M
|
$10.17 M
|
$6.67 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$18.98 M
|
$20.17 M
|
$12.53 M
|
$10.17 M
|
$6.67 M
|
| Other Expenses |
$0.00
|
$55.00 K
|
-$89.00 K
|
-$6.00 K
|
-$81.00 K
|
| Operating Expenses |
$56.61 M
|
$85.24 M
|
$66.02 M
|
$58.28 M
|
$27.71 M
|
| Cost And Expenses |
$56.61 M
|
$85.24 M
|
$66.02 M
|
$58.28 M
|
$27.71 M
|
| Interest Income |
$946.00 K
|
$258.00 K
|
$312.00 K
|
$1.06 M
|
$698.00 K
|
| Interest Expense |
$2.29 M
|
$1.99 M
|
$1.20 M
|
$650.00 K
|
$289.00 K
|
| Depreciation & Amortization |
$2.40 M
|
$313.00 K
|
$223.00 K
|
$1.73 M
|
$374.00 K
|
| EBITDA |
-$38.88 M |
-$75.01 M |
-$53.18 M |
-$42.40 M |
-$22.08 M |
| EBITDA Ratio |
-3
|
-7.81
|
-3.98
|
-3
|
-4.76
|
| Operating Income Ratio |
-3.37
|
-7.88
|
-3.94
|
-3.12
|
-4.98
|
| Total Other Income/Expenses Net |
$105.00 K
|
-$1.68 M
|
-$1.97 M
|
$198.00 K
|
$310.00 K
|
| Income Before Tax |
-$43.56 M
|
-$77.31 M
|
-$54.61 M
|
-$43.93 M
|
-$22.77 M
|
| Income Before Tax Ratio |
-3.37
|
-8.05
|
-4.08
|
-3.1
|
-4.91
|
| Income Tax Expense |
-$105.00 K
|
$925.00 K
|
$259.00 K
|
$644.00 K
|
$0.00
|
| Net Income |
-$43.46 M
|
-$78.24 M
|
-$54.87 M
|
-$44.57 M
|
-$22.77 M
|
| Net Income Ratio |
-3.36
|
-8.15
|
-4.1
|
-3.15
|
-4.91
|
| EPS |
-1.34 |
-31.92 |
-22.67 |
-27.53 |
-18.85 |
| EPS Diluted |
-1.34 |
-31.92 |
-22.67 |
-27.53 |
-18.85 |
| Weighted Average Shares Out |
$32.41 M
|
$2.45 M
|
$2.42 M
|
$1.62 M
|
$1.21 M
|
| Weighted Average Shares Out Diluted |
$32.41 M
|
$2.45 M
|
$2.42 M
|
$1.62 M
|
$1.21 M
|
| Link |
|
|
|
|
|
